David Sharp Joins Catalyst OrthoScience As VP of Global Marketing

David Sharp has joined Catalyst OrthoScience as Vice President of Global Marketing effective immediately.

“We are excited to have an executive with David’s experience join our team at Catalyst OrthoScience,” said Catalyst OrthoScience CEO and President Carl O’Connell. “As we continue to grow and establish our presence as an emerging global leader in shoulder pathology solutions, David’s leadership and experience will help make that vision a reality.”

“I am excited to join the Catalyst team and contribute to the company’s goals that focus on sustainable growth and delivering real solutions to clinical unmet needs for shoulder surgeons and their patients around the world,” Sharp said. “I will be focused on growing a best-in-class marketing team and brand as we continue to build our core foundations in sales, marketing, R&D, and MedEd.”

David Sharp brings more than 27 years of marketing, strategy, business development, communications and branding experience in the medical device industry, including roles with Sofamor Danek, Smith & Nephew, Medtronic Spinal & Biologics, Baxter International and most recently, MicroPort Orthopedics.

David Sharp received a Bachelor of Science in Business Administration from the University of Memphis and a Master’s in International Business from Christian Brothers University.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.